US Patent

US8686026 — Solid compositions

Formulation · Assigned to AbbVie Inc · Expires 2031-06-09 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects solid compositions made of amorphous Compound I, which can be formulated with a hydrophilic polymer and a surfactant.

USPTO Abstract

The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Drugs covered by this patent

Patent Metadata

Patent number: US8686026
Jurisdiction: US
Classification: Formulation
Expires: 2031-06-09
Drug substance claim: No
Drug product claim: Yes
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.